British in-vivo cell programming specialist Mogrify Ltd has added US$10m to its US$36m Series A financing.
Dyadic International Inc. and bYoRNA SAS partnered to advance innovative bioproduction technologies for scaling up the production of therapeutic mRNA from C1-Cells.
Biotech company, specialising in cell necrosis prevention, has announced a successful funding round, securing €1.2m in additional seed funding.
With more than 2,100 attendents, 4,700 partnering meetings so far, BioSpain 2023 is set to break records.
Pierre Fabre Laboratories, a leading French medical and beauty care company and Vernalis (R&D) Ltd, a fully owned subsidiary of HitGen Inc. and a specialist in drug discovery announce a long-term partnership for oncology drug discovery.
University of Sheffield spinout gets £5m for gene therapies targeting ALS and FTD, advancing towards clinical trials.
Oxford Biomedica’s proposed acquisition of ABL Europe from Institut Mérieux, at a consideration of €15m propels global leadership in cell and gene therapy.
Austrian Kern Tec GmbH has raised €12m in the biggest Series A financing ever seen for a foodtech company in Austria to scale food production from waste.
British drug discovery specialist BenevolentAI Ltd has licenced its end-to-end AI platform capabilities to Merck KGaA to deliver novel drug candidates for three targets in oncology, neurology and immunology.
Autoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic.